|Bid||9.84 x 2900|
|Ask||10.00 x 4000|
|Day's range||9.84 - 10.02|
|52-week range||8.46 - 12.40|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||6.44|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||0.48 (4.89%)|
|Ex-dividend date||23 Aug 2023|
|1y target est||14.78|
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your financial position. Three stocks that pay high yields and that could help accomplish this include Viatris (NASDAQ: VTRS), Verizon Communications (NYSE: VZ), and Altria Group (NYSE: MO). Generic and branded drugmaker Viatris has the potential to make for a stable long-term investment.
On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. Viatris (NASDAQ: VTRS), GSK (NYSE: GSK), and Organon (NYSE: OGN) are too inexpensive to pass up at this point. Let's look at some other reasons these three pharmaceutical stocks are too cheap to ignore.